Skip to main content

Availability of Orkambi on the NHS inquiry


The Committee’s inquiry concentrated on the provision and pricing of Orkambi, and other drugs developed by Vertex Pharmaceuticals for the treatment of cystic fibrosis. The Committee considered the positions taken in the negotiations between Vertex and NHS England, and NICE’s assessment of the cost-effectiveness of these drugs.

Upcoming events

View all events

No upcoming events scheduled

Contact us

We can't usually help you with an individual problem or a specific complaint.

  • Email:
  • Phone: (general enquiries) 020 7219 6182 | 020 7219 6832 (media enquiries)
  • Address: Health and Social Care Committee, House of Commons, London, SW1A 0AA